Trial Section
Home / Trial Section / Clinical Trial| Indication | Department | Study Title | Study Phase | Investigator | Contact Person | Status |
|---|---|---|---|---|---|---|
| Multiple Myeloma | Hematology and Oncology | An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER-MM3) | Phase III | Shih-Feng Cho | On-going | |
| Head and Neck Cancer | Hematology and Oncology | A Single Arm, Open label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy | Phase I | Hui-Ching Wang | 俞念廷 | On-going |
| Lymphoma | Hematology and Oncology | A Phase II, Open label, Single-arm, Multicenter Study of Chidamide in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma | Phase II | Yi-Chang Liu | On-going | |
| Non-Small Cell Lung Cancer | Chest Medicine | A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) | Phase II | Jen-Yu Hung | 董俞君 | On-going |
| Chest Medicine | Benefit Evaluation of Using “BreathePal” Bilevel Positive Pressure System for Patients with Respiratory Insufficiency | Class II | 鄭孟軒 | 洪苑真 | On-going | |
| Breast Cancer | Breast Oncology and Surgery | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase III | Ming-Feng Hou | 謝淑娟 | On-going |
| Diabetes Mellitus | Endocrinology and Metabolism | Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. once weekly versus tirzepatide 15 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor | Phase III | Mei-Yueh Lee | 郭盈蘭 | On-going |
| Lung Cancer | Chest Medicine | A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination with First-Line Afatinib in Patients with EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase II | Jen-Yu Hung | 周婉明 | On-going |
| Esophageal Cancer | Gastroenterology | A Phase 2, Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of LBL-007 in Combination With Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase II | I-Chen Wu | 郭靜芳 | On-going |
| Head and Neck Cancer | Hematology and Oncology | An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1 | Phase II | Hui-Ching Wang | 簡毓慧 | On-going |
← Please slide to the left for more information